Jennifer Dillaha, MD
NPI 1174722904 · Internal Medicine Physician · Little Rock, AR
Enrolled with Medicare as Practitioner - Infectious Disease · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1174722904
- Entity type
- Individual
- Primary specialty
- Internal Medicine PhysicianAllopathic & Osteopathic Physicians
- Credential
- MD
- Sex
- Female
- Sole proprietor
- No
- License
- E-1249 (AR)
Specialties & taxonomies
Allopathic & Osteopathic Physicians
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure28% of score
18 yrs in NPPES registry
- Profile completeness28% of score
100% of core fields populated
- Practice footprint17% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)28% of score
1,128 Medicare services, 2024 (ranked within specialty)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our methodology.
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Administration of Vaccine, Each Additional Vaccine90472 | 352 | $12 |
| Admn Sarscov2 Vacc 1 Dose90480 | 334 | $37 |
| Administration of Vaccine90471 | 191 | $17 |
| Detection Test By Immunoassay Technique for Severe Acute Respiratory Syndrome Coronavirus87426 | 127 | $35 |
| Administration of Influenza Virus VaccineG0008 | 111 | $21 |
| Detection Test By Multiplex Amplified Probe Technique for Severe Acute Respiratory Syndrome Coronavirus 2 (sars-Cov-2) (covid-19), Influenza Virus Types a and B, and Respiratory Syncytial Virus87637 | 13 | $140 |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 5 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Varicella-Zoster Ge/As01b/Pfbrand: Shingrix | 191 | 152 |
| Rsv Vacc, Pref a and Pref B/Pfbrand: Abrysvo | 57 | 57 |
| Rsvpref3 Antigen/As01e/Pfbrand: Arexvy | 55 | 55 |
| Diphth,pertuss(acell),tet Vacbrand: Boostrix Tdap | 20 | 20 |
| Tetanus-Diphtheria Toxoids/Pfbrand: Tenivac | 12 | 12 |
Medicare Part D only. These counts cover prescriptions paid through Medicare Part D in 2024 — they do notinclude cash-pay, commercial-insurance, Medicaid, or Part B–administered drugs, and badly undercount high cash-pay categories (e.g. GLP-1 weight-loss, testosterone, and ED medications). Any drug with 10 or fewer claims is omitted by CMS, and beneficiary counts under 11 are suppressed — so a missing drug means , never zero. This is a factual claims summary, not an endorsement, not medical advice, and not a consumer report. Source: CMS Medicare Part D Prescribers — by Provider and Drug.
Practice location
Mailing address
Registry dates
- Enumerated
- 2007-07-12
- Last updated
- 2007-07-12
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.